The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • eHealth software provider Respiri (RSH) has signed a service agreement with the Pharmacy Guild of Australia to help educate pharmacists on asthma management
  • The Pharmacy Guild represents over 5700 community pharmacies across the country
  • The asthma management will be an online training course with Guild Learning and Development
  • The program will also be supported by Respiri’s wheezo’s, which monitor asthma wheezing
  • On market close, Respiri is up 3.75 per cent and is selling shares for 8.3¢ each

eHealth software provider Respiri (RSH) has signed a service agreement with the Pharmacy Guild of Australia to help educate pharmacists on asthma management.

The Pharmacy Guild represents over 5700 community pharmacies across the country.

The agreement is for two years and the education program will be with Guild Learning and Development (GuildEd), which is a learning destination for Australian pharmacists, pharmacy assistants and interns.

The education program is an online training course for asthma patient management, in particular children. This will inform pharmacists to better help patients diagnosed with asthma.

The program will also be supported by Respiri’s wheezo’s, which monitor asthma wheezing.

Respiri CEO Marjan Mikel says with over 65,000 pharmacists practising in Australia, the company understands the importance of helping educate pharmacists.

“Respiri understands their [pharmacists] importance in helping patients with asthma better manage their condition ensuring a better health outcome and quality of life and the critical need for Respiri to build relationships with these key healthcare professionals to help them better understand how wheezo will help drive these patient outcomes,” he said.

“By educating pharmacists, who are an important intermediary between an asthmatic patient and their doctor and who already sell a range of asthmatic devices within the pharmacy setting, we see them as a critical determinant in building sales momentum and significant growth within this important channel,” he added.

On market close, Respiri is up 3.75 per cent and is selling shares for 8.3¢ each.

RSH by the numbers
More From The Market Online

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery

Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system